A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Part of paid clinical trials in Santa Barbara, California.

Sponsor
Eli Lilly and Company
Study ID
NCT06914895
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

Key Dates

Start date
Apr 25, 2025
Status verified
May 2026
Primary completion
Nov 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
905 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tirzepatide Dose 1
    Participants will receive tirzepatide subcutaneously (SC)
  • Experimental: Tirzepatide Dose 2
    Participants will receive tirzepatide SC
  • Experimental: Tirzepatide Dose 3
    Participants will receive tirzepatide SC
  • Experimental: Tirzepatide Dose 4
    Participants will receive tirzepatide SC
  • Placebo Comparator: Placebo
    Participants will receive placebo SC

Primary Outcome Measure

Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 40 ]

Locations (31)

FacilityCityStateZIPSite coordinators
Sansum Diabetes Research InstituteSanta BarbaraCalifornia93105-
Care Access - Santa ClaritaSanta ClaritaCalifornia91321-
University of Colorado Anschutz Medical CampusAuroraColorado80045-
Atlanta Diabetes AssociatesAtlantaGeorgia30318-
Orita Clinical ResearchDecaturGeorgia30034-
North Georgia Clinical ResearchWoodstockGeorgia30189-
East-West Medical Research InstituteHonoluluHawaii96814-
Rocky Mountain Clinical ResearchIdaho FallsIdaho83404-
Southern Illinois University School of MedicineSpringfieldIllinois62702-
Indiana University Health University HospitalIndianapolisIndiana46202-
Iowa Diabetes and Endocrinology Research CenterWest Des MoinesIowa50266-
Endocrine and Metabolic ConsultantsRockvilleMaryland20852-
HealthPartners Institute dba International Diabetes CenterMinneapolisMinnesota55416-
SKY Integrative Medical Center/SKYCRNGRidgelandMississippi39157-
Boeson Research MSOMissoulaMontana59804-
Palm Research Center SunsetLas VegasNevada89148-
Palm Research Center TenayaLas VegasNevada89128-
Albany Medical College, Division of Community EndocrinologyAlbanyNew York12203-
Research Foundation of SUNY - University of BuffaloBuffaloNew York14221-
NYC ResearchNew YorkNew York10016-
SUNY Upstate Medical UniversitySyracuseNew York13210-
Lucas Research, Inc.Morehead CityNorth Carolina28557-
Care Access - LimaLimaOhio45805-
Alliance for Multispecialty Research, LLCNormanOklahoma73069-
Suburban Research AssociatesWest ChesterPennsylvania19380-
Texas Diabetes & Endocrinology, P.A.AustinTexas78731-
Velocity Clinical Research, DallasDallasTexas75230-
Tekton Research, LLC.McKinneyTexas75069-
Medrasa Clinical ResearchWylieTexas75098-
Eastside Research AssociatesRedmondWashington98052-
Rainier Clinical Research CenterRentonWashington98057-

Find similar trials in Santa Barbara, CA

By condition
Obesity / overweightType 1 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Sansum Diabetes Research Institute· Santa Barbara, CACare Access - Santa Clarita· Santa Clarita, CAUniversity of Colorado Anschutz Medical Campus· Aurora, COAtlanta Diabetes Associates· Atlanta, GAOrita Clinical Research· Decatur, GANorth Georgia Clinical Research· Woodstock, GA

Related Studies